What question did this study set out to answer?

To evaluate the safety and efficacy of talquetamab in patients with relapsed or refractory AL amyloidosis.

December 8, 2025BloodOpen Access

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis

View Full Paper

Ask AI

Bookmark

To evaluate the safety and efficacy of talquetamab in patients with relapsed or refractory AL amyloidosis.
Multi-site retrospective case series
Included heavily pretreated patients with systemic light-chain amyloidosis
Assessed efficacy using International Society of Amyloidosis and European Hematology Association criteria
Minimal residual disease evaluated by multiparameter flow cytometry
Five of six patients achieved hematologic response (83%), with complete remission in all responders
MRD testing was negative in three tested patients
Safety profile included manageable cytokine release syndrome and some grade 1–3 adverse events

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective case series reports hematologic response in relapsed AL amyloidosis patients treated with talquetamab, suggesting a viable option for those with limited therapies.

Cite This Study

Ganayem et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6a5 https://doi.org/10.1182/blood-2025-7491

View Full Paper

Ask AI

Bookmark

Implication

Retrospective case series reports hematologic response in relapsed AL amyloidosis patients treated with talquetamab, suggesting a viable option for those with limited therapies.

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis

Key Points

Discussion

Implication

Cite This Study

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider